Pfizer Reports real-world evidence Data for Niraparib in Huntington's disease

Pfizer today announced real-world evidence results for Niraparib in patients with Huntington's disease. The study demonstrated that Niraparib achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Huntington's disease and support the continued development of Niraparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Niraparib was consistent with previous observations, with no new safety signals identified.